...introduction of product patent in India will reduce the accessibility and availability of medicines...Certain flexibility available under the TRIPS [Agreement on Trade-Related Aspects of Intellectual Property Rights] should be used to its full extent to safeguard accessibility and availability of drugs and medicines. The Bill, however, fails to make use of this flexibility... [refers to Novartis]